New findings in the pathogenesis of leprosy and implications for the management of leprosy

Current Opinion in Infectious Diseases

Volumn 26, Issue 5, 2013, Pages 413-419

  Polycarpou, Anastasia ^a   Walker, Stephen L ^a   Lockwood, Diana N ^a,b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b HOSPITAL FOR TROPICAL DISEASES   (United Kingdom)

Author keywords

erythema nodosum leprosum; leprosy; Mycobacterium leprae; Mycobacterium lepromatosis; type 1 reactions

Indexed keywords

ADIPOPHILIN; ALPHA DYSTROGLYCAN; ALPHA INTERFERON; BETA DEFENSIN 3; BETA INTERFERON; CD163 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FAT DROPLET; GALECTIN 3; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 17F; MICRORNA 21; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4;

ADAPTIVE IMMUNITY; BACTERIAL SURVIVAL; CELL DIFFERENTIATION; DENDRITIC CELL; DISEASE PREDISPOSITION; HUMAN; INNATE IMMUNITY; KERATINOCYTE; LEPROMATOUS LEPROSY; LEPROSY; LIPID METABOLISM; MACROPHAGE; MYCOBACTERIUM LEPRAE; MYCOBACTERIUM TUBERCULOSIS; NERVE CELL PLASTICITY; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PROGNOSIS; PROTEIN PHOSPHORYLATION; REVIEW; SCHWANN CELL; SKIN BIOPSY; SLIT SKIN SMEAR; SMEAR; TH17 CELL; TUBERCULOID LEPROSY;

HUMANS; LEPROSY; MYCOBACTERIUM LEPRAE;

EID: 84883600214     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e3283638b04     Document Type: Review

References (53)

1. Britton WJ, Lockwood DN. Leprosy. Lancet 2004; 363:1209-1219.
2. World Health Organization. Global leprosy situation. World Health Organization; 2012.
3. Ridley DS, Jopling WH. Classification of leprosy according to immunity. A fivegroup system. Int J Lepr Other Mycobact Dis 1966; 34:255-273.
4. Sarno EN, Grau GE, Vieira LM, Nery JA. Serum levels of tumour necrosis factor-alpha and interleukin-1 beta during leprosy reactional states. Clin Exp Immunol 1991; 84:103-108.
5. Wemambu SN, Turk JL, Waters MF, Rees RJ. Erythema nodosum leprosum: a clinical manifestation of the arthus phenomenon. Lancet 1969; 2:933-935.
6. Kahawita IP, Lockwood DN. Towards understanding the pathology of erythema nodosum leprosum. Trans R Soc Trop Med Hyg 2008; 102:329-337.
7. van Veen NH, Nicholls PG, Smith WC, Richardus JH. Corticosteroids for treating nerve damage in leprosy. Lepr Rev 2008; 79:361-371.
8. Cruz D, Watson AD, Miller CS, et al. Host-derived oxidized phospholipids and HDL regulate innate immunity in human leprosy. J Clin Invest 2008; 118:2917-2928.
9. Mattos KA, D'Avila H, Rodrigues LS, et al. Lipid droplet formation in leprosy: Toll-like receptor-regulated organelles involved in eicosanoid formation and Mycobacterium leprae pathogenesis. J Leukoc Biol 2010; 87:371-384.
10. Mattos KA, Oliveira VG, D'Avila H, et al. TLR6-driven lipid droplets in Mycobacterium leprae-infected Schwann cells: immunoinflammatory platforms associated with bacterial persistence. J Immunol 2011; 187:2548-2558.
11. Imamura M, Inoguchi T, Ikuyama S, et al. ADRP stimulates lipid accumulation and lipid droplet formation in murine fibroblasts. Am J Physiol Endocrinol Metab 2002; 283:E775-E783.
12. Egan JJ, Greenberg AS, Chang MK, et al. Mechanism of hormone-stimulated lipolysis in adipocytes: translocation of hormone-sensitive lipase to the lipid storage droplet. Proc Natl Acad Sci USA 1992; 89:8537-8541.
13. Tanigawa K, Suzuki K, Nakamura K, et al. Expression of adipose differentiation-related protein (ADRP) and perilipin in macrophages infected with Mycobacterium leprae. FEMS Microbiol Lett 2008; 289:72-79.
14. Tanigawa K, Degang Y, Kawashima A, et al. Essential role of hormonesensitive lipase (HSL) in the maintenance of lipid storage in Mycobacterium leprae-infected macrophages. Microb Pathog 2012; 52:285-291.
15. Degang Y, Akama T, Hara T, et al. Clofazimine modulates the expression of lipid metabolism proteins in Mycobacterium leprae-infected macrophages. PLoS Negl Trop Dis 2012; 6:e1936.
16. Rambukkana A, Salzer JL, Yurchenco PD, Tuomanen EI. Neural targeting of Mycobacterium leprae mediated by the G domain of the laminin-alpha2 chain. Cell 1997; 88:811-821.
17. Rambukkana A, Yamada H, Zanazzi G, et al. Role of alpha-dystroglycan as a Schwann cell receptor forMycobacterium leprae. Science 1998; 282:2076-2079.
18. Rambukkana A, Zanazzi G, Tapinos N, Salzer JL. Contact-dependent demyelination by Mycobacterium leprae in the absence of immune cells. Science 2002; 296:927-931.
19. Tapinos N, Ohnishi M, Rambukkana A. ErbB2 receptor tyrosine kinase signaling mediates early demyelination induced by leprosy bacilli. Nat Med 2006; 12:961-966.
20. Masaki T, Qu J, Cholewa-Waclaw J, et al. Reprogramming adult Schwann cells to stem cell-like cells by leprosy bacilli promotes dissemination of infection. Cell 2013; 152:51-67.
21. Liu PT, Wheelwright M, Teles R, et al. MicroRNA-21 targets the vitamin Ddependent antimicrobial pathway in leprosy. Nat Med 2012; 18:267-273.
22. Montoya D, Cruz D, Teles RM, et al. Divergence of macrophage phagocytic and antimicrobial programs in leprosy. Cell Host Microbe 2009; 6:343-353.
23. Teles RM, Graeber TG, Krutzik SR, et al. Type I interferon suppresses type II interferon-triggered human antimycobacterial responses. Science 2013; 339:1448-1453.
24. Moller HJ, Peterslund NA, Graversen JH, Moestrup SK. Identification of the hemoglobin scavenger receptor/CD163 as a natural soluble protein in plasma. Blood 2002; 99:378-380.
25. Moura DF, de Mattos KA, Amadeu TP, et al. CD163 favors Mycobacterium leprae survival and persistence by promoting anti-inflammatory pathways in lepromatous macrophages. Eur J Immunol 2012; 42:2925-2936.
26. Ogasawara N, Oguro T, Sakabe T, et al. Hemoglobin induces the expression of indoleamine 2,3-dioxygenase in dendritic cells through the activation of PI3K, PKC, and NF-kappaB and the generation of reactive oxygen species. J Cell Biochem 2009; 108:716-725.
27. de Souza Sales J, Lara FA, Amadeu TP, et al. The role of indoleamine 2, 3-dioxygenase in lepromatous leprosy immunosuppression. Clin Exp Immunol 2011; 165:251-263.
28. Schenk M, Krutzik SR, Sieling PA, et al. NOD2 triggers an interleukin-32-dependent human dendritic cell program in leprosy. Nat Med 2012; 18:555-563.
29. Chung AW, Sieling PA, Schenk M, et al. Galectin-3 regulates the innate immune response of human monocytes. J Infect Dis 2013; 207:947-956.
30. Cogen AL, Walker SL, Roberts CH, et al. Human beta-defensin 3 is upregulated in cutaneous leprosy type 1 reactions. PLoS Negl Trop Dis 2012; 6:e1869.
31. Walker SL, Roberts CH, Atkinson SE, et al. The effect of systemic corticosteroid therapy on the expression of toll-like receptor 2 and toll-like receptor 4 in the cutaneous lesions of leprosy Type 1 reactions. Br J Dermatol 2012; 167:29-35.
32. Kaplan G, Weinstein DE, Steinman RM, et al. An analysis of in vitro T cell responsiveness in lepromatous leprosy. J Exp Med 1985; 162:917-929.
33. Laal S, Sharma YD, Prasad HK, et al. Recombinant fusion protein identified by lepromatous sera mimics native Mycobacterium leprae in T-cell responses across the leprosy spectrum. Proc Natl Acad Sci USA 1991; 88:1054-1058.
34. Chaduvula M, Murtaza A, Misra N, et al. Lsr2 peptides of Mycobacterium leprae show hierarchical responses in lymphoproliferative assays, with selective recognition by patients with anergic lepromatous leprosy. Infect Immun 2012; 80:742-752.
35. Saini C, Prasad HK, Rani R, et al. Lsr2 of Mycobacterium leprae and its synthetic peptides elicit restitution of T cell responses in erythema nodosum leprosum and reversal reactions in patients with lepromatous leprosy. Clin Vaccine Immunol 2013; 20:673-682.
36. Palermo ML, Pagliari C, Trindade MA, et al. Increased expression of regulatory T cells and down-regulatory molecules in lepromatous leprosy. Am J Trop Med Hyg 2012; 86:878-883.
37. Attia EA, Abdallah M, Saad AA, et al. Circulating CD4\+ CD25 high FoxP3\+ T cells vary in different clinical forms of leprosy. Int J Dermatol 2010; 49:1152-1158.
38. Miossec P. IL-17 and Th17 cells in human inflammatory diseases. Microbes Infect 2009; 11:625-630.
39. da Motta-Passos I, Malheiro A, Gomes Naveca F, et al. Decreased RNA expression of interleukin 17A in skin of leprosy. Eur J Dermatol 2012; 22:488-494.
40. Kawaguchi M, Kokubu F, Huang SK, et al. The IL-17F signaling pathway is involved in the induction of IFN-gamma-inducible protein 10 in bronchial epithelial cells. J Allergy Clin Immunol 2007; 119:1408-1414.
41. Khader SA, Gopal R. IL-17 in protective immunity to intracellular pathogens. Virulence 2010; 1:423-427.
42. Chaitanya S, Lavania M, Turankar RP, et al. Increased serum circulatory levels of interleukin 17F in type 1 reactions of leprosy. J Clin Immunol 2012; 32:1415-1420.
43. Zenha EM, Wambier CG, Novelino AL, et al. Clinical and immunological evaluation after BCG-id vaccine in leprosy patients in a 5-year follow-up study. J Inflamm Res 2012; 5:125-135.
44. Martiniuk F, Giovinazzo J, Tan AU, et al. Lessons of leprosy: the emergence of TH17 cytokines during type II reactions (ENL) is teaching us about T-cell plasticity. J Drugs Dermatol 2012; 11:626-630.
45. Desvignes L, Ernst JD. Interferon-gamma-responsive nonhematopoietic cells regulate the immune response to Mycobacterium tuberculosis. Immunity 2009; 31:974-985.
46. Han XY, Seo YH, Sizer KC, et al. A new Mycobacterium species causing diffuse lepromatous leprosy. Am J Clin Pathol 2008; 130:856-864.
47. Han XY, Sizer KC, Thompson EJ, et al. Comparative sequence analysis of Mycobacterium leprae and the new leprosy-causing Mycobacterium lepromatosis. J Bacteriol 2009; 191:6067-6074.
48. Vera-Cabrera L, Escalante-Fuentes WG, Gomez-Flores M, et al. Case of diffuse lepromatous leprosy associated with 'Mycobacterium lepromatosis'. J Clin Microbiol 2011; 49:4366-4368.
49. Yang Han X, Clement Sizer K, Tan HH. Identification of the leprosy agent Mycobacterium lepromatosis in Singapore. J Drugs Dermatol 2012; 11:168-172.
50. Jessamine PG, Desjardins M, Gillis T, et al. Leprosy-like illness in a patient with Mycobacterium lepromatosis from Ontario, Canada. J Drugs Dermatol 2012; 11:229-233.
51. Han XY, Sizer KC, Velarde-Felix JS, et al. The leprosy agents Mycobacterium lepromatosis and Mycobacterium leprae in Mexico. Int J Dermatol 2012; 51:952-959.
52. Han XY, Jessurun J. Severe leprosy reactions due to Mycobacterium lepromatosis. Am J Med Sci 2013; 345:65-69.
53. Gillis TP, Scollard DM, Lockwood DN. What is the evidence that the putative Mycobacterium lepromatosis species causes diffuse lepromatous leprosy? Lepr Rev 2011; 82:205-209.